What Prenosis does

Prenosis is a Chicago-based AI diagnostics company founded in 2014 that develops precision medicine tools for acute care conditions, with its first commercial focus on sepsis. The company's lead product, the Sepsis ImmunoScore, is the first FDA-authorized AI diagnostic tool for sepsis (De Novo authorization, April 2024); it ingests 22 parameters including vital signs, routine labs, demographics, and biomarkers (CRP, procalcitonin) to predict sepsis onset and adverse outcomes within 24 hours, stratifying patients into four risk levels, and achieved an AUC of 0.82 in NEJM AI peer-reviewed validation. The Sepsis ImmunoScore is built on the Immunix precision medicine platform, which combines biological data from over 138,000 longitudinal blood specimens with clinical EMR data from 35,000+ patients collected across 11+ U.S. hospitals over more than a decade — claimed as the world's largest biological-clinical dataset for acute care patients with suspected infections.

Prenosis generates revenue through a combination of subscription/recurring AI diagnostic testing deployed via direct enterprise sales to hospital systems, platform licensing through an exclusive commercial distribution partnership with Roche Diagnostics via the Navify Algorithm Suite, and clinical trial network services supporting BARDA-funded studies. Its customer base is concentrated in U.S. large hospital systems, academic medical centers, and government healthcare programs (BARDA, NIH, DTRA), with the U.S. military and federal agencies representing adjacent non-dilutive funding channels. The company's primary GTM motions combine enterprise field sales targeting integrated delivery networks, channel distribution through Roche's established diagnostic footprint, and event-driven engagement with the sepsis and emergency medicine clinical community (Sepsis Alliance Summit, ACEP, World Sepsis Congress).

Strategically, Prenosis is positioned to extend beyond sepsis into adjacent acute care conditions (ARDS, AKI, AHF) using its Immunix platform, with a $20M BARDA Type to Treat Program contract funding expansion to up to 40 U.S. academic medical centers and a co-development collaboration with BioAegis Therapeutics for ARDS patient stratification. Recent milestones including SOC 2 Type II compliance (March 2026), a dedicated CMS ICD-10-PCS reimbursement code (effective October 2025), and a $20M Series A financing (January 2026) indicate the company is transitioning from a research-stage biobank operator to a scaled commercial diagnostics platform.

Name

Prenosis

Legal name

Prenosis, Inc.

Website

https://prenosis.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Prenosis is a Chicago-based AI diagnostics company that developed Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, built on its Immunix precision medicine platform combining a 138,000+ specimen biobank with clinical data, sold to U.S. hospital systems and distributed via Roche Diagnostics.

Ownership category

akta.pro rank

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Diagnostic Testing: Revenue generated from deployment of Sepsis ImmunoScore diagnostic tool to hospitals and healthcare systems. Tool integrates into hospital EMR workflow and generates risk assessments for patients.
2. Platform Licensing: Licensing of Immunix platform technology through distribution agreement with Roche Diagnostics for access to Sepsis ImmunoScore via Navify Algorithm Suite.
3. Clinical Trial Services: Precision medicine clinical trial network services enabling rapid identification of patients with specific biological profiles for therapeutic clinical trials, supporting BARDA-funded studies.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Prenosis develops and sells AI-powered diagnostic and predictive tools for acute care, primarily through its Sepsis ImmunoScore® product, the first FDA-authorized AI diagnostic for sepsis. The product is built on the proprietary Immunix® precision medicine platform that combines biological data from a large biobank with clinical EMR data. Products are sold to hospital systems via direct enterprise sales and through a distribution partnership with Roche Diagnostics, integrating directly into hospital EMRs.

Product overview

Prenosis offers a two-product portfolio built on its Immunix precision medicine platform: the Immunix platform itself (a biomarker-clinical data platform powering AI diagnostics) and Sepsis ImmunoScore (the first FDA-authorized AI diagnostic tool for sepsis, built on Immunix). Sepsis ImmunoScore integrates directly into hospital EMRs and is also distributed via Roche's Navify Algorithm Suite. The platform and product together enable precision medicine in acute care by combining biological data with clinical data to generate real-time predictive insights.

Differentiator

Problem solved

Functional benefit

Brands

• Immunix®: Precision medicine platform that enables the development and validation of new precision medicine solutions and their real-time implementation in clinical workflows.
• Sepsis ImmunoScore®

Products and services

• Immunix® Precision Medicine Platform Precision medicine platform that combines a proprietary biobank of over 138,000 longitudinal specimens and clinical data from 35,000+ patients across more than 11 U.S. hospitals to build AI-powered diagnostic and predictive tools for acute care conditions including sepsis, ARDS, AKI, and AHF. Targets hospital systems, academic medical centers, and pharmaceutical/diagnostic partners developing precision medicine solutions.
• Sepsis ImmunoScore® First FDA-authorized AI diagnostic tool for sepsis, using 22 parameters including biomarkers and clinical data to detect sepsis and predict adverse outcomes within 24 hours. Integrates directly into hospital EMRs and is available via Roche's Navify Algorithm Suite. Risk stratifies patients into four discrete categories (Very High, High, Medium, Low Risk). Sold to hospital systems and health networks for use in acute care settings.

Quantifiable outcome

• 15% higher accuracy in identifying patients meeting Sepsis-3 criteria compared to provider assessment alone
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered strategic and core.

• BioAegis TherapeuticsstrategicStrategic or Co-development Partner · 21 April 2026Collaboration to identify biological signatures and patient subpopulations that may benefit from BioAegis' gelsolin therapy using Prenosis' precision medicine platform to analyze biospecimens from Phase 2 ARDS clinical trial.
• Roche DiagnosticscoreChannel Partner/ Reseller/ Distributor · 10 April 2024Commercial distribution partnership making Sepsis ImmunoScore available through Roche's Navify Algorithm Suite platform, providing access to Roche's extensive hospital and laboratory customer base across the United States.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Dascena: Dascena develops machine-learning-based algorithms for early prediction of sepsis and other acute conditions in hospital settings. It is a direct competitor pursuing the same AI-enabled in-hospital sepsis prediction use case as Prenosis.
• Cytovale: Cytovale's IntelliSep is an FDA-cleared rapid cellular biomarker diagnostic for sepsis that delivers results in under 10 minutes. Like Prenosis, it sells an FDA-cleared sepsis diagnostic to U.S. hospitals, making it a direct peer in the same product category.
• Inflammatix: Inflammatix develops host-response-based diagnostics for acute infections and sepsis using machine learning on gene expression data. It targets the same clinical need — rapid, biology-driven sepsis diagnosis — with a complementary biomarker-plus-AI approach.
• T2 Biosystems: T2 Biosystems commercializes T2Bacteria, T2Candida, and the T2Dx instrument for direct-from-blood molecular detection of sepsis-causing pathogens. It competes in the same hospital sepsis diagnostic market, though using molecular rather than AI-biomarker methods.

Broad incumbents

• bioMérieux (BioFire Diagnostics): bioMérieux's BioFire FilmArray blood culture identification panels are widely deployed in U.S. hospital labs for rapid infectious disease diagnostics. As an established incumbent with broad diagnostic portfolios and large sales coverage, it competes in the same hospital sepsis workup category as Prenosis.
• Tempus AI: Tempus AI is a precision medicine platform combining multimodal biological and clinical data with AI to support diagnostics and therapeutics across multiple disease areas. It is a broader incumbent in data-driven precision medicine, overlapping with Prenosis's Immunix platform thesis.
• DeepHealth (RadNet): DeepHealth, acquired by RadNet, develops AI-powered diagnostic imaging software deployed across large hospital and imaging-center networks. It is comparable as a broader AI diagnostics incumbent selling into the same enterprise healthcare channel.

Emerging players

• Viz.ai: Viz.ai commercializes FDA-authorized AI algorithms integrated into hospital workflows for time-sensitive conditions (notably stroke). It is comparable as an emerging AI diagnostics company selling into the same enterprise hospital IT channel with EMR-embedded FDA-cleared algorithms.
• Digital Diagnostics (formerly IDx): Digital Diagnostics pioneered FDA-authorized autonomous AI diagnostics (IDx-DR for diabetic retinopathy). It is comparable to Prenosis as a peer in the small group of companies with de novo FDA authorizations for AI clinical diagnostics.
• Cleerly: Cleerly is an AI diagnostics company with FDA-cleared tools for cardiovascular disease detection integrated into clinical workflows. It is comparable as an emerging AI diagnostics peer pursuing FDA-authorized, EMR-integrated specialty diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/prenosis
• Xx.com/prenosisinc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prenosis